Matrin 3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about Matrin 3 Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases.
| Matrin 3 |
|---|
| Protein Name | Matrin 3 |
| Gene | MATR3 |
| UniProt ID | P43243 |
| PDB ID | 5D5G, 5VBY |
| Molecular Weight | 125 kDa |
| Subcellular Localization | Nuclear matrix, nuclear speckles |
| Protein Family | Matrin 3 family |
Matrin 3 is a highly acidic nuclear matrix protein with an N-terminal region containing two RNA recognition motifs (RRMs) and a C-terminal region with extensive heptad repeats that mediate homodimerization. The protein localizes to the nuclear matrix and speckles, where it participates in nuclear organization and RNA processing.
Matrin 3 is a nuclear matrix protein involved in multiple aspects of nuclear organization and RNA metabolism:
- RNA splicing: Component of the nuclear spliceosome, regulates alternative splicing
- Chromatin organization: Associates with nuclear matrix for chromatin architecture
- DNA repair: Participates in DNA damage response pathways
- TDP-43 interaction: Binds to TDP-43 and influences its nuclear localization
MATR3 mutations cause autosomal dominant ALS with both upper and lower motor neuron involvement:
- TDP-43 mislocalization: Loss of nuclear TDP-43 and cytoplasmic aggregation
- RNA splicing defects: Aberrant splicing of neuronal transcripts
- Nuclear envelope dysfunction: Disrupted nuclear pore and envelope integrity
Some MATR3 mutations cause FTD without motor neuron disease, suggesting phenotypic variability.
MATR3 mutations also cause an autosomal dominant distal myopathy affecting hand and foot muscles.
| Variant |
Disease |
Mechanism |
| S85C |
ALS |
Disrupted TDP-43 binding |
| P154A |
ALS/FTD |
Impaired RNA splicing |
| T622A |
MPD2 |
Muscle-specific dysfunction |
- Gene therapy: AAV-mediated delivery of wild-type MATR3
- Small molecule modulators: Enhance nuclear import or function
- ASOs: Antisense oligonucleotides targeting mutant alleles
- 24748764: MATR3 mutations in ALS. Nat. Neurosci, 2014.
- 26054668: Matrin 3 and TDP-43 interaction. Acta Neuropathol, 2015.
- 28988956: MATR3 in RNA processing. Brain, 2016.
MATR3 in disease:
- MATR3 mutations cause familial ALS
- p.P354S is the most common mutation
- Forms cytoplasmic inclusions
- Disrupts RNA metabolism
- MATR3 inclusions in FTD brain
- Overlaps with ALS pathology
- RNA granule dysfunction
- AAV-delivered wild-type MATR3
- CRISPR-based approaches
- Antisense oligonucleotides
- RNA granule modulators
- Protein aggregation inhibitors
- Neuroprotective compounds
- MATR3 knockout mice
- Patient-derived iPSCs
- Drosophila models
- Yeast models
- CSF MATR3 levels
- Genetic testing
- Clinical biomarkers
The study of Matrin 3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Johnson JO, et al. (2014). MATR3 mutations in ALS. Nat Neurosci 17(5):664-666.
- Bentmann E, et al. (2012). MATR3 pathology in ALS/FTD. Acta Neuropathol 124(5):681-692.
- Leblond CS, et al. (2019). MATR3 biology and disease. Brain 142(9):2573-2588.
- Johnson JO, et al. (2014). MATR3 mutations in ALS and FTD. Nat Neurosci 17: 664-666.
- Giordano G, et al. (2015). Matrin 3 interacts with TDP-43. Acta Neuropathol 130: 515-527.
- Leblond CS, et al. (2016). MATR3 and RNA splicing in neurodegeneration. Brain 139: 2743-2756.